디앤디파마텍

347850KOSDAQ

47.5 / 100

Reference Date: 2026-09-08

Financial Score15.5 / 40

News Sentiment19.0 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 13.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

D&D Pharmatech is a biopharmaceutical company specializing in developing innovative drugs for metabolic diseases, such as obesity and MASH (metabolic-associated steatohepatitis), and neurodegenerative disorders like Parkinson's and Alzheimer's, leveraging GLP-1-based peptide technology. The company's key pipelines include oral weight-loss medications and MASH treatments, with a business model focused on licensing and co-development with global partners. Additionally, it expands into areas such as PET biomarker development and alpha radiation-based cancer therapies through its subsidiaries.

Number of Employees

22people

Average Salary

169.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

—Industry Average 1.203.5Point

ROE

-32.29Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

16.64Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2024~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼62.4% (1-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼35.9% (1-year basis)

ROE Trend

0.0 / 4

Avg ROE -39.8% (improving, 2yr)

Detailed News Sentiment

16 totalPositive 12Neutral 2Negative 2Average Sentiment Score 75.9

Negative
17조 기술수출에도 소외되는 K-바이오…美와 엇갈린 주가, 무엇이 문제...
K-바이오의 미국 바이오 시장 대비 저조한 주가 성과로 인해 부정적인 영향이 예상됨.
Negative
[하우머니] 美 바이오는 사상 최고가, K-바이오는 왜 바닥인가
디앤디파마텍을 포함한 한국 바이오 기업들의 주가 하락이 글로벌 바이오 시장의 강세와 대조를 이루며 부정적 영향을 받고 있다.
Positive
디앤디파마텍, 중기부 AI 기반 신약개발 국책과제 선정
디앤디파마텍이 AI 기반 신약 개발 국책과제에 선정되어 IBD 치료제 개발에 대한 기대감이 높아졌다.

Detailed Momentum

52-week position1.0Point

Near 52w low (13%, downtrend)

Current 49,700Won52-week high 111,20052-week low 40,040

1-month return1.0Point

1m -13.57% (falling)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral투자판단관련주요경영사항(임상시험결과) (대사이상지방간염 (MASH) 치료제 DD01의 미국 임상 제2상 임상시험결과보고서(CSR) 수령)2026-08-21
Neutral반기보고서 (2026.06)2026-08-14